DYNAMICS OF LIVER FIBROSIS MARKERS AND INSULIN RESISTANCE DURING TREATMENT WITH SODIUM–GLUCOSE COTRANSPORTER 2 (SGLT-2) INHIBITORS
Keywords:
Type 2 diabetes mellitus, MAYJK, SGLT-2 inhibitors, Fib-4, liver fibrosis, NAFLD fibrosis score, insulin resistancyAbstract
This study evaluated the effect of SGLT-2 inhibitors on liver fibrosis indices (Fib-4, NAFLD fibrosis score) and insulin resistance (HOMA-IR) in patients with type 2 diabetes, as well as the correlation between these variables. The results demonstrated a statistically significant decrease in Fib-4 and NFS values following therapy, along with a strong positive correlation between fibrosis indices and HOMA-IR (ρ >0.85; p < 0.001). These findings support the hepatoprotective and metabolic effects of SGLT-2 inhibitors.
References
Eslam M. et al. "MAFLD: A consensus-driven proposed nomenclature for metabolic associated fatty liver disease." J Hepatol, 2020.
Younossi Z.M. et al. "Global epidemiology of NAFLD." Hepatology, 2016.
Dulai P.S. et al. "Increased risk of mortality by fibrosis stage in NAFLD: Systematic review and meta-analysis." Hepatology, 2017.
European Association for the Study of the Liver (EASL). "EASL Clinical Practice Guidelines on non-invasive tests for evaluation of liver disease severity and prognosis." J Hepatol, 2021.
Takahashi H. et al. "Empagliflozin improves liver steatosis and fibrosis in type 2 diabetes patients with NAFLD." Diabetes Care, 2020.
Kuchay M. et al. "Dapagliflozin in the treatment of NAFLD in patients with type 2 diabetes." Diabetes Care, 2018.
Sattar N., McGuire D.K. "SGLT2 inhibitors and cardiovascular risk: Lessons from large outcome trials." Lancet Diabetes Endocrinol, 2019.
Sterling R.K. et al. "Development of a simple noninvasive index to predict significant fibrosis in patients with NAFLD." Hepatology, 2006.
Angulo P. et al. "The NAFLD fibrosis score: A noninvasive system to identify patients with liver fibrosis." Hepatology, 2007.
Matthews D.R. et al. "Homeostasis model assessment: insulin resistance and beta-cell function." Diabetologia, 1985.
